(IVZ) Invesco - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: BMG491BT1088
ETF, Mutual Fund, Portfolio Management, Separate Account
Dividends
| Dividend Yield | 3.18% |
| Yield on Cost 5y | 5.71% |
| Yield CAGR 5y | 1.27% |
| Payout Consistency | 90.6% |
| Payout Ratio | 43.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 33.3% |
| Value at Risk 5%th | 51.6% |
| Relative Tail Risk | -5.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 32.47 |
| CAGR/Max DD | 0.50 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.550 |
| Beta | 1.498 |
| Beta Downside | 1.826 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.52% |
| Mean DD | 13.60% |
| Median DD | 14.28% |
Description: IVZ Invesco November 03, 2025
Invesco Ltd. (NYSE: IVZ) is a global investment manager that serves a broad client base-including retail, institutional, high-net-worth, public entities, and sovereign wealth funds-through a suite of equity, fixed-income, multi-asset, commodity, and alternative strategies delivered via mutual funds, ETFs, and private funds.
As of the most recent filing, Invesco reported $1.6 trillion in assets under management (AUM), with a 4.2 % year-over-year growth driven largely by inflows into its active equity and ESG-focused products. The firm’s revenue mix remains heavily weighted toward fee income (≈ 85 % of total revenue), making it sensitive to fee compression trends and the ongoing shift toward low-cost passive investing. Key sector drivers include rising demand for quantitative and factor-based strategies, as well as regulatory scrutiny on fee disclosures that could affect profitability.
For a deeper quantitative view of Invesco’s valuation and risk profile, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (998.9m TTM) > 0 and > 6% of Revenue (6% = 457.1m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -6.87% (prev 20.51%; Δ -27.37pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 1.39b > Net Income 998.9m (YES >=105%, WARN >=100%) |
| Net Debt (-973.1m) to EBITDA (1.37b) ratio: -0.71 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (454.6m) change vs 12m ago -0.22% (target <= -2.0% for YES) |
| Gross Margin 42.97% (prev 32.44%; Δ 10.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 27.24% (prev 21.41%; Δ 5.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 17.23 (EBITDA TTM 1.37b / Interest Expense TTM 71.9m) >= 6 (WARN >= 3) |
Altman Z'' 1.55
| (A) -0.02 = (Total Current Assets 973.1m - Total Current Liabilities 1.50b) / Total Assets 28.44b |
| (B) 0.25 = Retained Earnings (Balance) 7.17b / Total Assets 28.44b |
| (C) 0.04 = EBIT TTM 1.24b / Avg Total Assets 27.97b |
| (D) 0.53 = Book Value of Equity 7.17b / Total Liabilities 13.65b |
| Total Rating: 1.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.55
| 1. Piotroski 6.50pt |
| 2. FCF Yield 7.82% |
| 3. FCF Margin 18.03% |
| 4. Debt/Equity 0.54 |
| 5. Debt/Ebitda -0.71 |
| 6. ROIC - WACC (= 1.81)% |
| 7. RoE 6.99% |
| 8. Rev. Trend 32.34% |
| 9. EPS Trend -10.02% |
What is the price of IVZ shares?
As of December 06, 2025, the stock is trading at USD 26.24 with a total of 10,728,122 shares traded.
Over the past week, the price has changed by +7.32%, over one month by +13.27%, over three months by +20.38% and over the past year by +53.08%.
Over the past week, the price has changed by +7.32%, over one month by +13.27%, over three months by +20.38% and over the past year by +53.08%.
Is IVZ a buy, sell or hold?
Invesco has received a consensus analysts rating of 3.07.
Therefor, it is recommend to hold IVZ.
- Strong Buy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the IVZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.4 | 0.5% |
| Analysts Target Price | 26.4 | 0.5% |
| ValueRay Target Price | 28.2 | 7.4% |
IVZ Fundamental Data Overview December 02, 2025
Market Cap USD = 11.00b (11.00b USD * 1.0 USD.USD)
P/E Trailing = 16.7755
P/E Forward = 10.101
P/S = 1.7517
P/B = 0.9898
P/EG = 0.4451
Beta = 1.643
Revenue TTM = 7.62b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.37b USD
Long Term Debt = 1.62b USD (from longTermDebt, last quarter)
Short Term Debt = 66.2m USD (from shortTermDebt, last fiscal year)
Debt = 7.55b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -973.1m USD (from netDebt column, last quarter)
Enterprise Value = 17.57b USD (11.00b + Debt 7.55b - CCE 973.1m)
Interest Coverage Ratio = 17.23 (Ebit TTM 1.24b / Interest Expense TTM 71.9m)
FCF Yield = 7.82% (FCF TTM 1.37b / Enterprise Value 17.57b)
FCF Margin = 18.03% (FCF TTM 1.37b / Revenue TTM 7.62b)
Net Margin = 13.11% (Net Income TTM 998.9m / Revenue TTM 7.62b)
Gross Margin = 42.97% ((Revenue TTM 7.62b - Cost of Revenue TTM 4.34b) / Revenue TTM)
Gross Margin QoQ = 54.05% (prev 33.28%)
Tobins Q-Ratio = 0.62 (Enterprise Value 17.57b / Total Assets 28.44b)
Interest Expense / Debt = 0.34% (Interest Expense 25.7m / Debt 7.55b)
Taxrate = 3.06% (9.70m / 317.1m)
NOPAT = 1.20b (EBIT 1.24b * (1 - 3.06%))
Current Ratio = 0.65 (Total Current Assets 973.1m / Total Current Liabilities 1.50b)
Debt / Equity = 0.54 (Debt 7.55b / totalStockholderEquity, last quarter 14.01b)
Debt / EBITDA = -0.71 (Net Debt -973.1m / EBITDA 1.37b)
Debt / FCF = -0.71 (Net Debt -973.1m / FCF TTM 1.37b)
Total Stockholder Equity = 14.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.51% (Net Income 998.9m / Total Assets 28.44b)
RoE = 6.99% (Net Income TTM 998.9m / Total Stockholder Equity 14.28b)
RoCE = 7.79% (EBIT 1.24b / Capital Employed (Equity 14.28b + L.T.Debt 1.62b))
RoIC = 8.79% (NOPAT 1.20b / Invested Capital 13.67b)
WACC = 6.98% (E(11.00b)/V(18.54b) * Re(11.54%) + D(7.55b)/V(18.54b) * Rd(0.34%) * (1-Tc(0.03)))
Discount Rate = 11.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.17%
[DCF Debug] Terminal Value 70.92% ; FCFE base≈1.41b ; Y1≈1.74b ; Y5≈2.97b
Fair Price DCF = 65.80 (DCF Value 29.29b / Shares Outstanding 445.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -10.02 | EPS CAGR: -8.75% | SUE: 3.09 | # QB: 1
Revenue Correlation: 32.34 | Revenue CAGR: 15.02% | SUE: 3.45 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=+0.004 | Revisions Net=+6 | Analysts=7
EPS next Year (2026-12-31): EPS=2.49 | Chg30d=+0.050 | Revisions Net=+4 | Growth EPS=+25.4% | Growth Revenue=+14.1%
P/E Trailing = 16.7755
P/E Forward = 10.101
P/S = 1.7517
P/B = 0.9898
P/EG = 0.4451
Beta = 1.643
Revenue TTM = 7.62b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.37b USD
Long Term Debt = 1.62b USD (from longTermDebt, last quarter)
Short Term Debt = 66.2m USD (from shortTermDebt, last fiscal year)
Debt = 7.55b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -973.1m USD (from netDebt column, last quarter)
Enterprise Value = 17.57b USD (11.00b + Debt 7.55b - CCE 973.1m)
Interest Coverage Ratio = 17.23 (Ebit TTM 1.24b / Interest Expense TTM 71.9m)
FCF Yield = 7.82% (FCF TTM 1.37b / Enterprise Value 17.57b)
FCF Margin = 18.03% (FCF TTM 1.37b / Revenue TTM 7.62b)
Net Margin = 13.11% (Net Income TTM 998.9m / Revenue TTM 7.62b)
Gross Margin = 42.97% ((Revenue TTM 7.62b - Cost of Revenue TTM 4.34b) / Revenue TTM)
Gross Margin QoQ = 54.05% (prev 33.28%)
Tobins Q-Ratio = 0.62 (Enterprise Value 17.57b / Total Assets 28.44b)
Interest Expense / Debt = 0.34% (Interest Expense 25.7m / Debt 7.55b)
Taxrate = 3.06% (9.70m / 317.1m)
NOPAT = 1.20b (EBIT 1.24b * (1 - 3.06%))
Current Ratio = 0.65 (Total Current Assets 973.1m / Total Current Liabilities 1.50b)
Debt / Equity = 0.54 (Debt 7.55b / totalStockholderEquity, last quarter 14.01b)
Debt / EBITDA = -0.71 (Net Debt -973.1m / EBITDA 1.37b)
Debt / FCF = -0.71 (Net Debt -973.1m / FCF TTM 1.37b)
Total Stockholder Equity = 14.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.51% (Net Income 998.9m / Total Assets 28.44b)
RoE = 6.99% (Net Income TTM 998.9m / Total Stockholder Equity 14.28b)
RoCE = 7.79% (EBIT 1.24b / Capital Employed (Equity 14.28b + L.T.Debt 1.62b))
RoIC = 8.79% (NOPAT 1.20b / Invested Capital 13.67b)
WACC = 6.98% (E(11.00b)/V(18.54b) * Re(11.54%) + D(7.55b)/V(18.54b) * Rd(0.34%) * (1-Tc(0.03)))
Discount Rate = 11.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.17%
[DCF Debug] Terminal Value 70.92% ; FCFE base≈1.41b ; Y1≈1.74b ; Y5≈2.97b
Fair Price DCF = 65.80 (DCF Value 29.29b / Shares Outstanding 445.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -10.02 | EPS CAGR: -8.75% | SUE: 3.09 | # QB: 1
Revenue Correlation: 32.34 | Revenue CAGR: 15.02% | SUE: 3.45 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=+0.004 | Revisions Net=+6 | Analysts=7
EPS next Year (2026-12-31): EPS=2.49 | Chg30d=+0.050 | Revisions Net=+4 | Growth EPS=+25.4% | Growth Revenue=+14.1%
Additional Sources for IVZ Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle